Systematic cardio-oncologic screening of patients treated with BRAF and MEK inhibitors
Despite a predominantly low HFA-ICOS risk profile, nearly one-fifth of patients in this contemporary cohort developed significant cardiovascular complications, including symptomatic heart failure and new-onset arrhythmias, so a proactive and multidisciplinary monitoring strategy is mandatory for all patients receiving...